New hope for lung cancer patients who stopped responding to targeted pills
NCT ID NCT05870319
First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-squamous lung cancer that has a specific EGFR gene change and has stopped responding to targeted therapy. The goal is to see if SKB264 alone can help people live longer without their cancer growing. Participants are randomly assigned to receive either SKB264 or chemo, and the study is open-label, meaning both doctors and patients know which treatment is given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.